GlucoTrack
GCTK
2 hedge funds and large institutions have $60.2K invested in GlucoTrack in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
78% less capital invested
Capital invested by funds: $273K → $60.2K (-$213K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$45.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$204K |
| 2 |
AWM
Accurate Wealth Management
Wesley Chapel,
Florida
|
-$18.1K |
| 3 |
VCM
Virtue Capital Management
Brentwood,
Tennessee
|
-$12.6K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$7.27K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.52K |
GCTK Hedge Fund Activity: Q2 2024 in Review
2 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in GlucoTrack (GCTK) for Q2 2024, worth a combined $60.2K — down 78% from $273K a quarter earlier.
Fund positioning in GCTK was balanced in Q2 2024: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was Cetera Investment Advisers, opening a new position worth an estimated $45.2K. The largest seller was Sabby Management, exiting entirely with an estimated $204K sold.
- 2 institutional investors held GlucoTrack (GCTK) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $60.2K of GlucoTrack stock for Q2 2024, down 78% quarter-over-quarter.
- 1 fund opened new GlucoTrack positions in Q2 2024 and 1 closed out, a net change of 0 holders.
- The largest GlucoTrack buyer in Q2 2024 was Cetera Investment Advisers, an estimated $45.2K added.
- The largest GlucoTrack seller in Q2 2024 was Sabby Management, an estimated $204K sold.
Based on aggregated 13F filings for Q2 2024.